Interpreting steep dose-response curves in early inhibitor discovery

Journal of Medicinal Chemistry

Volumn 49, Issue 25, 2006, Pages 7274-7277

  Shoichet, Brian K ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR;

ARTICLE; BINDING AFFINITY; COLLOID; CURVE FITTING; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITOR INTERACTION; IC 50; INHIBITION KINETICS; MODEL; PHASE TRANSITION; PRECIPITATION; STOICHIOMETRY; ULTRAVIOLET RADIATION;

ACETOPHENONES; BENZOPYRANS; BETA-LACTAMASES; COLLOIDS; CONGO RED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; MODELS, BIOLOGICAL; PHENOLPHTHALEINS; PROTEIN BINDING;

EID: 33845491449     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm061103g     Document Type: Article

References (16)

1. Lipinski, C.; Hopkins, A. Navigating chemical space for biology and medicine. Nature 2004, 432, 855-861.
2. Stockwell, B. R. Exploring biology with small organic molecules. Nature 2004, 432, 846-854.
3. Rishton, G. M. Nonleadlikeness and leadlikeness in biochemical screening. Drug Discovery Today 2003, 8, 86-96.
4. Hann, M. M.; Oprea, T. I. Pursuing the leadlikeness concept in pharmaceutical research. Curr. Opin. Chem. Biot. 2004, 8, 255-263.
5. Walters, W.; Namchuk, M. Designing screens: how to make your hits a hit. Nat. Rev. Drug Discovery 2003, 2, 259-266.
6. Inglese, J.; Auld, D. S.; Jadhav, A.; Johnson, R. L.; Simeonov, A.; Yasgar, A.; Zheng, W.; Austin, C. P. Quantitative high-throughput screening; a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 11473-11478.
7. Black, J. A personal view of pharmacology. Ann. Rev. Pharmacol. Toxicol. 1996, 36, 1-33.
8. Segel, I. H. Enzyme Kinetics; Wiley: New York, 1975; p 957.
9. McGovern, S. L.; Shoichet, B. K. Kinase inhibitors: not just for kinases anymore. J. Med. Chem. 2003, 46, 1478-1483.
10. Shoichet, B. K. Screening in a spirit haunted world. Drug Discovery Today 2006, 11, 607-615.
11. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J. Med. Chem. 2002, 45, 1712-1722.
12. Seidler, J.; McGovem, S. L.; Doman, T. N.; Shoichet, B. K. Indentification and prediction of promiscuous drugs. J. Med. Chem. 2003, 46, 4477-4486.
13. Straus, O. H.; Goldstein, A. Zone behavior of enzymes: illustrated by the effect of dissociation constant and dilution on the system cholinesterase- physostigmine. J. Gen. Physiol. 1943, 26, 559-585.
14. Easson, L. H.; Stedman, E. The absolute activity of choline-esterase. Proc. R. Soc. London. Ser. B 1936, 121, 142-164.
15. Usher, K.; Shoichet, B. K.; Blaszczak, L.; Weston, G. S.; Remington, J. R. The three dimensional structure of AmpC β-lactamase from Escherichia coli bound to a transition-state analog: possible implications for the oxyanion hypothesis and for inhibitor design. Biochemistry 1998, 37, 16082-16092.
16. Feng, B. Y.; Shelat, A.; Doman, T. N.; Guy, R. K.; Shoichet, B. K. High-throughput assays for promiscuous inhibitors. Nat. Chem. Biol. 2005, 1, 146-148.